keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/28645446/cost-effectiveness-analysis-of-two-treatment-strategies-for-chronic-hepatitis-c-before-and-after-access-to-direct-acting-antivirals-in-spain
#1
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado
OBJECTIVE: To evaluate the cost-effectiveness of a strategy based on direct-acting antivirals (DAAs) following the marketing of simeprevir and sofosbuvir (post-DAA) versus a pre-direct-acting antiviral strategy (pre-DAA) in patients with chronic hepatitis C, from the perspective of the Spanish National Health System. METHODS: A decision tree combined with a Markov model was used to estimate the direct health costs (€, 2016) and health outcomes (quality-adjusted life years, QALYs) throughout the patient's life, with an annual discount rate of 3%...
June 20, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28643186/current-progress-in-host-innate-and-adaptive-immunity-against-hepatitis-c-virus-infection
#2
REVIEW
Jijing Shi, Yuanyuan Li, Wenxian Chang, Xuexiu Zhang, Fu-Sheng Wang
Hepatitis C virus (HCV) infects more than 170 million people worldwide and is the main cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Although the newly developed direct-acting antivirals (DAAs) have transformed the treatment of HCV infection, controlling HCV infection on a global scale remains a challenge because of the high cost, low resistance barrier of DAAs and lack of HCV vaccine. The host immune responses associated with HCV infection, especially HCV-specific T cellular immunity, determine the outcome of HCV infection: either acute or chronic infection...
June 22, 2017: Hepatology International
https://www.readbyqxmd.com/read/28634131/cost-effectiveness-of-pre-versus-post-liver-transplant-hepatitis-c-treatment-with-direct-acting-antivirals
#3
Sumeyye Samur, Brian Kues, Turgay Ayer, Mark S Roberts, Fasiha Kanwal, Chin Hur, Drew Michael S Donnell, Raymond T Chung, Jagpreet Chhatwal
BACKGROUND & AIMS: Oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment offer new hope to both pre- and post-liver transplant (LT) patients. However, whether to treat HCV patients pre- versus post-LT is not clear, as treatment can improve liver function but could reduce the chance of receiving a LT while on the waiting list. Our objective was to evaluate the cost-effectiveness of pre-LT versus post-LT HCV treatment with oral DAAs in decompensated cirrhotic patients on the LT waiting list...
June 17, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28631044/-personalized-treatment-of-viral-hepatitis-of-the-present-and-the-future-hepatitis%C3%A2-b-c-delta-and-e
#4
REVIEW
R Bartenschlager, M Cornberg, T Pietschmann
Precision medicine is also possible for infectious diseases as shown for the treatment of chronic viral hepatitis, especially if different options are available. In hepatitis B virus (HBV) infection, treatment indication as well as the choice of treatment and the decisions to stop treatment are based on viral markers and alanine aminotransferase (ALT) level. Future therapies for HBV infection aiming for functional cure or even virus elimination may be even more personalized and have to take into account the immune status of a given patient...
June 19, 2017: Der Internist
https://www.readbyqxmd.com/read/28628931/-the-probabilistic-efficiency-frontier-a-value-assessment-of-treatment-options-in-hepatitis-c
#5
Axel C Mühlbacher, Andrew Sadler
Background The German Institute for Quality and Efficiency in Health Care (IQWiG) recommends the concept of the efficiency frontier to assess health care interventions. The efficiency frontier supports regulatory decisions on reimbursement prices for the appropriate allocation of health care resources. Until today this cost-benefit assessment framework has only been applied on the basis of individual patient-relevant endpoints. This contradicts the reality of a multi-dimensional patient benefit. Objective The objective of this study was to illustrate the operationalization of multi-dimensional benefit considering the uncertainty in clinical effects and preference data in order to calculate the efficiency of different treatment options for hepatitis C (HCV)...
June 19, 2017: Das Gesundheitswesen
https://www.readbyqxmd.com/read/28608576/evaluation-of-three-techniques-for-detection-of-il28b-snp-a-prognostic-tool-for-hcv-treatment-outcome
#6
Bushra Khubaib, Muhammad Idrees, Zareen Fatima, Madiha Akram, Samia Afzal, Iram Amin, Muhammad Shahid, Muhammad Wasim
OBJECTIVE: The study was accompanied to evaluate the specificity, cost and turn-around time of three different types of techniques that can be used for analysis of single nucleotide polymorphism of rs129796860. METHODS: One hundred and one samples of patients infected with chronic Hepatitis C were genotyped with the three types of genotyping methods: direct sequencing, SNaPshot PCR and PCR-Restriction fragment Length polymorphism. RESULTS: Three distinct profiles for IL28B rs12979860 alleles (CC, CT and TT) were obtained with direct sequencing; SNaPshot PCR and PCR-RFLP and the results were consistent among the three methods...
June 13, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28605444/is-elimination-of-hepatitis-c-from-the-uk-by-2030-a-realistic-goal
#7
Will Gelson, Graeme Alexander
Introduction: Highly effective, combination therapy for chronic hepatitis C virus (HCV) infection is now available. Current cure rates are close to 100% and applicable to all patients irrespective of race, age, severity of liver disease or viral genotype. Remarkably for persistent infection, current treatment is recommended for as little as 12 weeks; recent studies suggest even shorter courses. In contrast to interferon-based therapy, present regimens have few side effects and serious adverse events are rare...
June 9, 2017: British Medical Bulletin
https://www.readbyqxmd.com/read/28604141/cost-effectiveness-of-subdermal-implantable-buprenorphine-versus-sublingual-buprenorphine-to-treat-opioid-use-disorder
#8
John A Carter, Ryan Dammerman, Michael Frost
AIMS: Subdermal implantable buprenorphine (BSI) was recently approved to treat opioid use disorder (OUD) in clinically-stable adults. In the pivotal clinical trial, BSI was associated with a higher proportion of completely-abstinent patients (85.7% vs 71.9%; P = 0.03) versus sublingual buprenorphine (SL-BPN). Elsewhere, relapse to illicit drug use is associated with diminished treatment outcomes and increased costs. Herein, we evaluated the cost-effectiveness of BSI versus SL-BPN from a US societal perspective...
June 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28594786/hospitalizations-for-endocarditis-and-associated-health-care-costs-among-persons-with-diagnosed-drug-dependence-north-carolina-2010-2015
#9
Aaron T Fleischauer, Laura Ruhl, Sarah Rhea, Erin Barnes
Opioid dependence and overdose have increased to epidemic levels in the United States. The 2014 National Survey on Drug Use and Health estimated that 4.3 million persons were nonmedical users of prescription pain relievers (1). These users are 40 times more likely than the general population to use heroin or other injection drugs (2). Furthermore, CDC estimated a near quadrupling of heroin-related overdose deaths during 2002-2014 (3). Although overdose contributes most to drug-associated mortality, infectious complications of intravenous drug use constitute a major cause of morbidity leading to hospitalization (4)...
June 9, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28594677/the-ethics-cost-and-evidence-surrounding-current-pharmacological-treatment-of-hepatitis-c-virus-infection
#10
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Clinical Nurse Specialist CNS
https://www.readbyqxmd.com/read/28594667/the-ethics-cost-and-evidence-surrounding-current-pharmacological-treatment-of-hepatitis-c-virus-infection
#11
Patricia Anne O'Malley
No abstract text is available yet for this article.
July 2017: Clinical Nurse Specialist CNS
https://www.readbyqxmd.com/read/28591243/platelet-count-squared-spleen-diameter-aspartate-aminotransferase-ratio-non-invasive-method-to-predict-esophageal-varices
#12
Ângelo Zambam de Mattos, Larissa Faraco Daros, Angelo Alves de Mattos
BACKGROUND: - Variceal bleeding has a high mortality among cirrhotics, and screening with endoscopy is indicated at the diagnosis of cirrhosis. Screening with endoscopy implies discomfort, risks and considerable costs. OBJECTIVE: - To evaluate platelet count squared/spleen diameter-aspartate aminotransferase ratio (PS/SA), as a non-invasive predictor of esophageal varices in cirrhotics. METHODS: - This cross-sectional study evaluated cirrhotics for PS/SA and presence of esophageal varices...
May 25, 2017: Arquivos de Gastroenterologia
https://www.readbyqxmd.com/read/28581634/no-one-size-fits-all-shortening-duration-of-therapy-with-direct-acting-antivirals-for-hepatitis-c-genotype-1-infection
#13
Omar El Sherif, Nezam Afhdal, Michael Curry
The advent of shorter duration, highly effective and well tolerated interferon-free therapy now provides an opportunity for virtually all HCV infected individuals to be cured. However, there continues to be a need to simplify and shorten treatment duration. Shortening therapy to 8 weeks with sofosbuvir and ledipasvir can be considered in treatment patients with HCV genotype 1 infection and low baseline viral load. A number of other 8 week dual and triple therapy direct acting antiviral (DAA) regimens are in advanced clinical development...
June 5, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28579812/cost-per-care-of-the-first-year-of-direct-antiviral-agents-in-the-liguria-region-a-multicenter-analysis
#14
Giovanni Cenderello, Caterina Fanizza, Simona Marenco, Laura Ambra Nicolini, Stefania Artioli, Isabella Baldissarro, Chiara Dentone, Pasqualina De Leo, Antonio Di Biagio
AIMS: Despite the remarkable efficacy shown in clinical practice, concerns have been raised about the costs associated with direct antiviral agent (DAA) therapy. This article presents the real-life costs for DAA treatment sustained by the Italian National Health Service in the Liguria Region (Northern Italy). METHODS: A retrospective analysis of the cost per care sustained for DAA treatment, relating to the period from January 1 to December 31, 2015 in five centers in Liguria was performed...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28577690/value-of-comprehensive-hcv-treatment-among-vulnerable-high-risk-populations
#15
Gigi A Moreno, Alice Wang, Yuri Sánchez González, Oliver Díaz Espinosa, Diana K Vania, Brian R Edlin, Ronald Brookmeyer
OBJECTIVES: The objective of this study was to explore the trade-offs society and payers make when expanding treatment access to patients with chronic hepatitis C virus (HCV) infection in early stages of disease as well as to vulnerable, high-risk populations, such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM-HIV). METHODS: A discrete time Markov model simulated HCV progression and treatment over 20 years. Population cohorts were defined by behaviors that influence the risk of HCV exposure: PWID, MSM-HIV, an overlap cohort of individuals who are both PWID and MSM-HIV, and all other adults...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28567430/can-hepatitis-c-virus-antigen-testing-replace-ribonucleic-acid-polymearse-chain-reaction-analysis-for-detecting-hepatitis-c-virus-a-systematic-review
#16
REVIEW
Harun Khan, Andrew Hill, Janice Main, Ashley Brown, Graham Cooke
The complexity and cost of current diagnostics for hepatitis C virus (HCV) may act as a prevention to the scale-up of treatment in the developing world. Currently, ribonucleic acid (RNA)-polymerase chain reaction tests are the gold standard. However, there is potential for the use of simpler and cheaper antigen tests to confirm HCV infection in different clinical settings. We evaluated the sensitivity and specificity of antigen assays. This was compared with the reference-standard RNA assays. A subanalysis also assessed Architect core antigen test, which is the only commercially available antigen test on the market...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28562549/identification-of-groups-with-poor-cost-effectiveness-of-peginterferon-plus-ribavirin-for-na%C3%A3-ve-hepatitis-c-patients-with-a-real-world-cohort-and-database
#17
Pei-Chien Tsai, Ta-Wei Liu, Yi-Shan Tsai, Yu-Min Ko, Kuan-Yu Chen, Ching-Chih Lin, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Nai-Jen Hou, Chung-Feng Huang, Ming-Lun Yeh, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming-Lung Yu
BACKGROUND: For decades, peginterferon and ribavirin (PegIFN/RBV) have been the standard-of-care for chronic hepatitis C virus (CHC) infection. However, the actual cost-effectiveness of this therapy remains unclear. We purposed to explore the real-world cost effectiveness for subgroups of treatment-naïve CHC patients with PegIFN/RBV therapy in a large real-world cohort using a whole population database. METHODS: A total of 1809 treatment-naïve chronic hepatitis C virus (HCV) patients (829 HCV genotype 1 [G1] and 980 HCV G2) treated with PegIFN/RBV therapies were linked to the National Health Insurance Research Database, covering the entire population of Taiwan from 1998 to 2013 to collect the total medical-care expenses of outpatient (antiviral agents, nonantiviral agents, laboratory, and consultation costs) and inpatient (medication, logistic, laboratory, and intervention costs) visits...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28557994/the-societal-cost-of-heroin-use-disorder-in-the-united-states
#18
Ruixuan Jiang, Inyoung Lee, Todd A Lee, A Simon Pickard
OBJECTIVE: Heroin use in the United States has reached epidemic proportions. The objective of this paper is to estimate the annual societal cost of heroin use disorder in the United States in 2015 US dollars. METHODS: An analytic model was created that included incarceration and crime; treatment for heroin use disorder; chronic infectious diseases (HIV, Hepatitis B, Hepatitis C, and Tuberculosis) and their treatments; treatment of neonatal abstinence syndrome; lost productivity; and death by heroin overdose...
2017: PloS One
https://www.readbyqxmd.com/read/28553150/hepatitis-c-infection-in-egypt-prevalence-impact-and-management-strategies
#19
REVIEW
Asmaa Gomaa, Naglaa Allam, Aisha Elsharkway, Mohamed El Kassas, Imam Waked
Hepatitis C virus (HCV) infection is a major public health burden in Egypt, where it bears the highest prevalence rate in the world. Estimates for prevalence are based upon data reported from the 2008 and 2015 Egypt Demographic Health Surveys. In this review, we demonstrate the prevalence results of both surveys and analyze the difference in the results. The overall HCV prevalence is estimated to be declining. However, the clinical impact of chronic HCV infection is expected to grow considerably. A mathematical model shows that by increasing the rate of treatment, the expected number of patients will decline significantly in 2030...
2017: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/28544048/use-of-electronic-health-record-clinical-decision-support-tool-for-hcv-birth-cohort-screening
#20
David N Fitch, Ajay Dharod, Claudia L Campos, Marina Núñez
The United States Preventive Services Task Force (USPSTF) recommended one-time HCV testing for all patients in the 1945-1965 birth cohort, given the high hepatitis C virus (HCV) prevalence in this group [1]. In response, various interventions differing in complexity and cost have been developed. Goel et al, evaluated a multifaceted intervention sequentially implemented and report poor response to the electronic health record (EHR) alert and a very successful HCV screening, increased by 137%, after adding other tools including physician education, data feedback, and patient navigation [2]...
May 24, 2017: Journal of Viral Hepatitis
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"